DOI 10.3324/haematol.2024.286002
Frequency of secondary T-cell lymphoma in chimeric antigen receptor T-cell naïve B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy.
Аннотация
Аннотация не предоставлена источником. Содержательный обзор этой публикации недоступен.
Перевод полного текста: Перевод в очереди
Полный текст источника
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( by-nc 4.0 ) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Chimeric antigen receptor (CAR) T-cell therapies improve clinical outcomes for diffuse large B-cell lymphoma (DL-BCL) and other B-cell lymphoid lineage cancers (B-LC). 1-3 Today, more than 27,000 CAR T-cell doses have been administered in the US. 4 A recent case series identified 22 patients developing T-cell lymphoma (TCL) after CAR T-cell therapy. The Food and Drug Administration (FDA) has issued a warning on all six approved CAR T-cell products based on these findings. For now, the benefits of CAR T-cell therapies seem to outweigh this risk. First reported in a CAR T-cell treated case-series, three of the 22 US CAR T-cell-associated TCL cases demonstrated evidence of clonal similarity to the CAR T-cell product, while another large center reports no clonal relationship between the DLBCL and secondary TCL. 5 Further, the crude rate of T-cell malignancies was only 0.1% in FAERS data 6 and 0.1% to 0.2% in two single-center studies. 5 , 7 However, such rates typically underestimate the cumulative incidence without accounting for effects of follow-up time, competing risks, frontline chemoimmunotherapy, and increased likelihood of performing new biopsies in this patient population. As such, data on the background risk of TCL among CAR T-cell naïve patients with relapsed or refractory (R/R) DLBCL or other primary B-LC diagnoses are warranted.
In this study, we investigated the cumulative incidence of TCL for CAR T-cell naïve patients with a diagnosis of DLBCL, mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM); four B-LC approved for CAR T-cell therapies by the FDA. Additionally, we assessed the cumulative incidence of TCL in patients with R/R DLBCL considered eligible for CAR T-cell therapy. All data were retrieved from the Danish Lymphoid Cancer Research (DALY-CARE) data resource. 8 We included all Danish patients registered with a diagnosis of DLBCL, MCL, CLL, and MM between January 2002 and February 2023 for whom pathology notes were available until May 2023. To exclude concomitant B-LC and TCL diagnoses, patients were first considered at risk 3 month after B-LC diagnosis and followed until TCL, death, or end of follow-up, whichever came first. From January 2005, patients with R/R DLBCL after frontline therapy and younger than 70 years were retrospectively considered eligible for CAR T-cell therapy. CAR T-cell therapy was first approved by the Danish Medicines Council in September 2023 for patients with early R/R DLBCL younger than 70 years, and all patients in this study are thus CAR T-cell therapy naïve. The study was approved by the Danish Health Data Authority and National Ethics Committee (approvals P-2020-561 and 1804410, respectively).
We included 10,805 patients with DLBCL (C83.3), 1,515 with MCL (C83.1), 13,773 with CLL/SLL (C83.0 and C91.1), and 10,994 with MM (C90.0). After a median follow-up of 8.5 years (interquartile range [IQR], 4.6-13.5) from time of diagnosis ( Table 1 ), we identified 127 patients with a secondary biopsy-verified TCL: 36 (28%) with peripheral TCL not otherwise specified (C84.4), 28 (22%) with anaplastic large cell lymphoma (C84.6), 27 (22%) with angioimmunoblastic TCL (C86.5), 18 (14%) with mycosis fungoides (C84.0), eight (6.3%) with cutaneous TCL not otherwise specified (C84.8), and ten with other TCL. The overall 1-, 2-, and 5-year cumulative incidence of TCL was 0.11%, 0.17%, and 0.28%, respectively. Stratified on disease, the 5-year cumulative incidence of TCL was 0.56% (N=55), 0.30% (N=4), 0.23% (N=29), and 0.07% (N=7) in patients with DLBCL, MCL, CLL, and MM, respectively ( Figure 1A ). In a subset of 1,051 patients younger than 70 years with R/R DLBCL after frontline therapy, who today could be considered CAR T-cell treatment eligible in Denmark, the 1-year cumulative incidence of TCL from time of relapse was 0.77% (N=8) and plateaued during 5 years of follow-up ( Figure 1B ). On the other hand, the median overall survival (OS) from time of DLBCL relapse was only 3.8 years (95% confidence interval [CI]: 3.0-4.7 years), despite significantly improved OS in recent years (Figure 2; P =0.035). Of note, only 319 (30.4%) RR DLBCL patients received high-dose therapy followed by an autologous stem cell transplant.
Table 1.
Baseline characteristics at time of diagnosis.
In these population-based, CAR T-cell naïve cohorts, the 5-year incidence of TCL from diagnosis of DLBCL was low, but higher than for patients with CLL or MM. For the patients younger than 70 years at time of R/R DLBCL, who would be considered eligible for CAR T-cell therapy today, the cumulative incidence of TCL was 0.77% after 1 year of follow-up. This is higher than reported in US patients having undergone CAR T-cell therapy (0.14% or 17 cases per 12,394 patients). The crude rate of TCL after CAR T-cell therapy in the US was thus lower compared to the cumulative incidence after just 14 months from time of diagnosis (overall x-intercept for 0.14%) and to the cumulative incidence after 7.5 months from DLBCL diagnosis (Figure 1A; DLBCL x-intercept for 0.14%). Importantly, two large single-center studies have each reported a single clonally unrelated TCL case among 724 (0.14%) and 449 (0.22%) T-cell therapy recipients, which support a very low incidence of secondary TCL after CAR T-cell therapies. 5 , 7 Our study is limited by the retrospective design and the fact that risk of a second primary malignancy is associated with chemotherapy exposure, 9 while shorter survival in the CAR T-cell naïve R/R DLBCL population reduces the time at risk of a secondary malignancy. 10 However, developing TCL after a diagnosis of DLBCL, CLL, and MM rarely occurs in CAR T-cell-treated 6 and naïve patients, whereas CAR T-cell-treated children do not develop TCL at all. 11 Among R/R DLBCL patients considered eligible for CAR T-cell treatment, the cumulative incidence of secondary TCL was markedly higher than what has been reported for patients upon CAR T-cell therapy. 6 Although reporting TCL as an adverse event in the case studies from CAR T-cell-treated cohorts may occur, the here reported population-based data on the background risk of TCL in comparable patient populations emphasize that the benefits of CAR T-cell therapies greatly outweighs the risk of CAR T-cell-derived TCL. Despite improved survival for patients with R/R DLBCL in recent years as a likely result of better patient selection, supportive care and bispecific therapy in clinical trials, 12 we underscore the urgent need for improved therapy in this patient population.


Data-sharing statement
Data may be shared on the Danish Lymphoid Cancer Research (DALY-CARE) data resource on a collaborative basis. Data may not be shared publicly
References
1. San-Miguel J Dhakal B Yong K . Cilta-cel or standard care in lenalidomide-refractory multiple myeloma . N Engl J Med . 2023 ; 389 ( 4 ): 335 - 347 . 37272512 10.1056/NEJMoa2303379
2. Westin JR Oluwole OO Kersten MJ . Survival with axicabtagene ciloleucel in large B-cell lymphoma . N Engl J Med . 2023 ; 389 ( 2 ): 148 - 157 . 37272527 10.1056/NEJMoa2301665
3. Coombs CC Easaw S Grover NS O’Brien SM . Cellular therapies in chronic lymphocytic leukemia and Richter’s transformation: recent developments in chimeric antigen receptor T-cells, natural killer cells, and allogeneic stem cell transplant . Cancers (Basel) . 2023 ; 15 ( 6 ): 1838 . 36980726 10.3390/cancers15061838 PMC10046903
4. Verdun N Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy . N Engl J Med . 2024 ; 390 ( 7 ): 584 - 586 . 38265704 10.1056/NEJMp2400209
5. Hamilton MP Sugio T Noordenbos T . Risk of second tumors and T-cell lymphoma after CAR T-cell therapy . N Engl J Med . 2024 ; 390 ( 22 ): 2047 - 2060 . 38865660 10.1056/NEJMoa2401361 PMC11338600
6. Elsallab M Ellithi M Lunning MA . Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System . Blood . 2024 ; 143 ( 20 ): 2099 - 2105 . 38483155 10.1182/blood.2024024166
7. Ghilardi G Fraietta JA Gerson JN . T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy . Nat Med . 2024 ; 30 ( 4 ): 984 - 989 . 38266761 10.1038/s41591-024-02826-w
8. Brieghel C Werling M Frederiksen CM . The Danish Lymphoid Cancer Research data resource: the basis for developing datadriven hematology . medRxiv . 2024 .04.11.24305663. doi: https://doi. org/10.1101/2024.04.11.24305663 [pre-print, not peer-reviewed].
9. da Cunha-Bang C Rostgaard K Andersen MA . Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study . Br J Haematol . 2021 ; 193 ( 2 ): 339 - 345 . 33570184 10.1111/bjh.17337
10. Arboe B Olsen MH Gørløv JS . Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study . Clin Epidemiol . 2019 ; 11 : 207 - 216 . 30881137 10.2147/CLEP.S178003 PMC6407517
11. Lamble AJ Schultz LM Nguyen K . Risk of T-cell malignancy following CAR T cells in children, adolescents and young adults . Blood Adv . 2024 ; 8 ( 13 ): 3544 - 3548 . 38701425 10.1182/bloodadvances.2024013243 PMC11261075
12. Kyvsgaard ER Riley C Clausen MR . Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy . Br J Haematol . 2024 ; 204 ( 1 ): 356 - 360 . 37830381 10.1111/bjh.19156
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.